EMA Authorised: LysaKare (L-arginine hydrochloride;L-lysine hydrochloride) — Novartis Europharm Limited

View source ↗

Summary

The EMA has authorised LysaKare (L-arginine hydrochloride; L-lysine hydrochloride) for use in radiation injuries.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Radiation Injuries

Drugs mentioned

• LysaKare

Snippet

Status: Authorised. Therapeutic area: Radiation Injuries. MAH: Novartis Europharm Limited. Decision date: 21/07/2026